Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mensa is really on a mission over y! $ONCS board...
Is this an old OncoSec logo or what?
Dilution and no news for 3 months.
For more than a week, $ONCS MB is sitting in the top 40-45 most read board with more than 10 000 reads a day.
I think many investors are sitting on the sideline waiting for that run to start and probably chase it. It might give us some gas for that run.
It is just a matter of time guys
Thought he mentioned something about leverage for negotiation during one of the multiple event he attended during spring.
Would it be a good deal if we get Milestone $$$ but givin away some of the shares from S-3?
We were told a part of it would be used for a partnership...
Punit mentionned $ONCS can fully finance a Phase IIb with the last offering, so we might get the same deal.
We don't see $$ now, but good results will definitely lead to $$$$.
Another doctor on our board ?
How can you buy MORE when you sold everything last week ?
IMO nothing will happen at $ONCS until this gets approval. When it does, we might finally see Phase IIb with or without partnership.
Expecting for thoses results?
I expect them when they'll start lining up events again.
Must running out of quotes!
False alarm for what exactly?
lol... you offer more entertainment than Sedrik's strategy
Are we going to start to speculate that Punit is finalizing a deal with Merck, that they are in quiet period or maybe writing the PR for next monday.
Anything to distract us from watching the PPS every 5 min.
Funny how PPS moved up when this board started to be more optimistic.
I wouldn't say it was raw guts, it just feel logical givin' all we know from $ONCS and not being emotional about recent PPS action.
And seriously, what HCIT means? Can't be "How Cool Is That" or "Healthcare Information Technology"
I guess it makes sense.
Would love see a PR like :
OncoSec presents promising P2 data, initiates P2B with ... [Insert big Pharma here] with a 100M+ agreement on milestones reached.
I've seen it a couple of times 100k share bought and similar amount sold not long after.
Would they really get the P2Final out on a non-event? Isn't the kind of thing you want to present in a conference or something.
I think we're all hopefull about a partnership for Phase IIB.
But Piazzo had a hint that it may take a bit longer than we expect as they need some stuff done before.
According to the messages we receive from IR, they will achieve their 2014 Milestones this fall which should include launching Phase IIB.
I think you can wait, conference is in Octobe
Probably already posted, but this is Dr. Axel Hauschild resentation at EADO.
http://www.eado2014.com/user/_files/62/008_Axel_Hauschild_Immunopulse.Hauschild.EADO.2014.pdf
I wanted to know about those 2 points on slide 16? I expected only 1 new "trial"
- New indication (IL-12)
- New Immuno-modulatory Target ID and Validation
How does it sound like combo trial?
Clinical response and immune correlates of intratumoral electroporation of IL-12 in advanced melanoma.
I tried to help you talking about GALT this morning... saying they Acorn was not always good evaluating good management.
Just kidding...
I really think we're at the good place at the right time with $ONCS. I'm just not as experienced as other investors here.
This is my first OTC stock I decided to invest in last November and got my first investing lesson with June's dilution.
Of course I've heard of INO... If I check other companies, many had run than pull back in the same area it started, a bit like our february run. I wonder if these cycle are timed with their 6 months cycle Tremors mentioned... somehow.
I'm just being cautious too, I definitely should take profit in the next run thought, way too much invested in $ONCS but also thinking to buy more theses days.
I just checked Acorn web site and the list of their clients,
First is Galectin Therapeutics Inc. (GALT) which has a class action lawsuit against them.
Doesn't start really well..
ARTH and HPEV are 2 other PPS I checked, they both have some kind of a similar "hype" as ONCS. But I didn't check any news about them. At least they have a recovery after their fall.
Thanks for the info, I already felt that nothing will come out during the summer, as Patrick said it's really calm in Biotechs. Only thing they did was to write some blog posts.
Selling never crossed my mind yet, let's just say I'm REALLY looking forward for a something "solid" from them.
Punit also talks about "significant developments" for this fall in is blog posts. It should only be positive for us.
And yes, I had a good trip thank you. It was quite challenging thought.
Damage is done, IBB is recovering and we're not.
Was just saying that fall looks promising speaking of news that can bring us back up closer to dollar range.
I'm getting a bit impatient concerning :
- Phase II that they could finance completely like they said.
- New trial
I want something else than a new Phd on the board. I saw that last one is specialized in Breast, Colorectal, Head and Neck, Lymphomas cancers.
We can guess he was appointed for the new trial...
We've taken a big hit, can't read all those 1000s messages I missed though.
But I've just read Punit's Blog Post, I guess he feels the fear in shareholders.
http://punitdhillon.com/2014/08/06/doctor-quit-yellen-at-janet/
I'm quite confident for this fall: just one big news needed.
Our excellent management team remains in place; our cash position is stronger than ever; we are rapidly expanding our pipeline to address a wide variety of immune targets and tumor indications; our core technology continues to demonstrate a potential to fundamentally impact the cancer treatment landscape and provide serious benefit to a large number of patients; our advisory board and stakeholders are comprised of the best and brightest in the field; and we have several key milestones planned for 2014 that we believe are of unprecedented significance for the company.
Me too, everybody wanted a PR about that conference, we have a blog post from Pierce and everybody seems to ignore it.
It just confirmed that there was no new data presented and we just need to sit tight, go through a couple of painful weeks until they get their stuff done and hopefully enjoy the ride. or i go bust.. :(
Been adding from 0.30s to 0.60 back to 0.40s now. Never sold a single share. I think the down trend got rid of the quick flippers and probably continue.
I may post some pessimist thoughts sometimes, I just think this is NOT a short term position. Incredible results so far, only complaints about twitter usage and PR releases. They still communicate far more than many other penny stock IMO.
Out for vacation, hope to get back to civilization with a PPS still over 0.40s tho :)
Dr. Pierce :
Both of these two talks paired very well with the presentation that I gave entitled “Intralesional DNA Immunotherapy: Converting Anti-PD-1 Non-Responders to Responders.” In this talk, I highlighted emerging data showing that – at least in melanoma – it is the high TIL/high PD-L1 patients, who represent the anti-PD-1 responder population and how the great unmet medical need now is figuring out how to convert low TIL into high TIL patients. In my opinion, we will need to reverse the immunosuppressive tumor microenvironment directly with local intralesional therapy, using potent pro-inflammatory molecules, like IL-12. In support of this hypothesis, I showed some data from our patients treated with intratumoral electroporation of DNA-encoded IL-12 as well as some of our mouse model data. I believe these data, though preliminary, paint the picture that intratumoral electroporation of IL-12 is driving a conversion from a low to a high TIL phenotype and this supports our rationale for a combination approach with an anti-PD-1 (or, anti-PD-L1) mAb.
“I Am ImmunoPulse!”
$ONCS blog written by Pierce, I would guess. our superhero ;)
Much appreciated Jeff
Everytime someone compare $ONCS to another which had a huge run, they are not on OTC. Were they uplisted after (INO, RNN, CPRX) ?
I just ask because I wonder if they will let us pass 2.00$ (minimum for uplisting). Or they will and bring it under before 5 days
And from Punit's letter, they are highly respected investors... They don't have my respect if they really did what you said.
The latest cash raise was the largest financing in company history and involved highly respected institutional biotechnology investors
We are all waiting for the big ride, just easier to wait under the sun than rain. We'll eventually get there.
Not a quick flip like some might think
@trading_jeff @Th3Accountant you noted "quiet period" it's a term used when a company is waiting for a registration to go effective.
Was refering to the S-3
Seeing the global market falling today, no idea what kind of support we can have here.
Thought quiet period means not talk at all...